Breviscapine attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis via activation of NRF2/SLC7A11/GPX4 pathway
- 1Division of Cardiac Care Unit, Department of Cardiology, Wuhan Asia Heart Hospital
- 2Department of Cardiology, Hubei Provincial Hospital of Traditional Chinese Medicine
- 3Hubei University of Chinese Medicine
Abstract
To explore the protective effect of Breviscapine against myocardial ischemia-reperfusion (I/R) injury and its mechanism. The in vivo and in vitro models of myocardial I/R injury were first established and treated with different concentrations of Bre. The myocardial infarct size was measured, while histopathological changes of myocardial tissue were evaluated by hematoxylin-eosin (HE) staining, and cardiac function-related parameters were assessed via echocardiography. Prussian blue staining was performed to visualize ferroptosis; enzyme-linked immunosorbent assay (ELISA) was used to detect the expression levels of creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH); flow cytometry was employed to determine the apoptosis rate of cardiomyocytes. Western blot (WB) and qRT-PCR were conducted to examine the levels of ferroptosis-related molecules (NOX1, NRF2, GPX4 and SLC7A11), respectively. Meanwhile, oxidative stress-related indices associated with ferroptosis, such as malondialdehyde (MDA), superoxide dismutase (SOD) and reactive oxygen species (ROS), were determined. Finally, a specific NRF2 inhibitor was administered for intervention, and changes in the above indicators were observed. Bre dose-dependently alleviated myocardial histological damage, reduced infarct size, improved cardiac function (elevated EF/FS, decreased LVEDV/LVESV), and inhibited cardiomyocyte apoptosis. Bre also suppressed ferroptosis, as shown by reduced Fe²⁺accumulation, MDA, GSSG, ROS, and NOX1 expression, and enhanced SOD activity, GSH content, and NRF2/SLC7A11/GPX4 expression. NRF2 inhibitor ML385 reversed these effects. Bre alleviates myocardial I/R injury by inhibiting ferroptosis via activating the NRF2/SLC7A11/GPX4 pathway.
Related
- Inclisiran attenuates myocardial ischemia/reperfusion injury by inhibiting macrophage M1 polarization
- Electroacupuncture pretreatment attenuates myocardial ischemia/reperfusion injury-induced ferroptosis via the p53/SLC7A11/GPX4 pathway
- Statement of Retraction: Baicalin regulates macrophages polarization and alleviates myocardial ischaemia/reperfusion injury via inhibiting JAK/STAT pathway.
- Blocking MyD88 Signaling Pathway Protects Against Myocardial Ischemia Reperfusion by Inhibiting NOX/ROS Pathway and Enhancing eNOS Activity
- PMEPA1 attenuates myocardial ischemia-reperfusion injury via interaction with NEDD4 and involvement of the TGF-β/SMAD pathway
BibTeX
@article{tan2026breviscapine,
title = {{Breviscapine attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis via activation of NRF2/SLC7A11/GPX4 pathway}},
author = {An’an Tan and Yingzhe Xiong and Jiawei Wu and Qiangqiang Tian and Chen Chen},
journal = {Scientific Reports},
year = {2026},
month = sep,
doi = {10.1038/s41598-026-72823-1},
url = {https://doi.org/10.1038/s41598-026-72823-1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Breviscapine attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis via activation of NRF2/SLC7A11/GPX4 pathway
AU - An’an Tan
AU - Yingzhe Xiong
AU - Jiawei Wu
AU - Qiangqiang Tian
AU - Chen Chen
PY - 2026
DA - 2026/09/01
JO - Scientific Reports
DO - 10.1038/s41598-026-72823-1
UR - https://doi.org/10.1038/s41598-026-72823-1
AB - To explore the protective effect of Breviscapine against myocardial ischemia-reperfusion (I/R) injury and its mechanism. The in vivo and in vitro models of myocardial I/R injury were first established and treated with different concentrations of Bre. The myocardial infarct size was measured, while histopathological changes of myocardial tissue were evaluated by hematoxylin-eosin (HE) staining, and cardiac function-related parameters were assessed via echocardiography. Prussian blue staining was performed to visualize ferroptosis; enzyme-linked immunosorbent assay (ELISA) was used to detect the expression levels of creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH); flow cytometry was employed to determine the apoptosis rate of cardiomyocytes. Western blot (WB) and qRT-PCR were conducted to examine the levels of ferroptosis-related molecules (NOX1, NRF2, GPX4 and SLC7A11), respectively. Meanwhile, oxidative stress-related indices associated with ferroptosis, such as malondialdehyde (MDA), superoxide dismutase (SOD) and reactive oxygen species (ROS), were determined. Finally, a specific NRF2 inhibitor was administered for intervention, and changes in the above indicators were observed. Bre dose-dependently alleviated myocardial histological damage, reduced infarct size, improved cardiac function (elevated EF/FS, decreased LVEDV/LVESV), and inhibited cardiomyocyte apoptosis. Bre also suppressed ferroptosis, as shown by reduced Fe²⁺accumulation, MDA, GSSG, ROS, and NOX1 expression, and enhanced SOD activity, GSH content, and NRF2/SLC7A11/GPX4 expression. NRF2 inhibitor ML385 reversed these effects. Bre alleviates myocardial I/R injury by inhibiting ferroptosis via activating the NRF2/SLC7A11/GPX4 pathway.
SN - 2045-2322
ER -